Tradestie Institutional Equity Comparison Engine
BLTE vs BHST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BLTE Overall Edge
BLTE Captures Institutional Edge (2โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Belite Bio, Inc American Depositary Shares (BLTE) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, BLTE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, BLTE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BLTE N/M vs BHST N/M Fwd P/E
Growth & Margin Winner
BLTE
Op Margin 0.0% vs -18.0% ยท YoY +0.0% vs +3.8%
Momentum & Technical Winner
BLTE
1Y +5.8% vs -79.4% ยท 52W Pos 23% vs 6%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BLTE
NASDAQ
Belite Bio, Inc American Depositary Shares
Pharmaceutical Preparations
$127.38
-15.65% 1D
Market Cap
$5.4B
1M Return
-15.23%
1Y Return
+5.83%
Forward P/E
N/M
Unified AI Score
39.7 / 100
SELL
Tech 23.0
Fund 42.0
Flow 50.0
Mom 60.0
BHST
NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap
$29.9M
1M Return
-22.62%
1Y Return
-79.4%
Forward P/E
N/M
Unified AI Score
58.2 / 100
HOLD
Tech 75.0
Fund 57.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BLTE +5.83%
BHST -79.4%
Spread: +85.23 pp (BLTE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BLTE TTM Op. Margin: 0.0%
BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLTE vs BHST. Trailing 12-month operating profitability (BLTE 0.0% vs BHST -18.0%) and valuation multiples (BLTE N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BLTE | BHST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.4B | $29.9M | Larger Scale | BLTE |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +3.8% | Higher Growth | BHST |
| Operating Margin (TTM) Profitability | 0.0% | -18.0% | Higher Margin | BLTE |
| Net Profit Margin Profitability | 0.0% | -31.2% | Higher Margin | BLTE |
| Return on Equity (ROE) Capital Efficiency | -21.2% | -142.5% | Higher ROE | BLTE |
| 52-Week Range Position Momentum | 23% ($106โ$200) | 6% ($1โ$7) | Stronger Trend | BLTE |
| Beta / 30D Volatility Risk Regime | 1.31ฮฒ ยท 71% Vol | 0.25ฮฒ ยท 86% Vol | Lower Realized Risk | BLTE |
| Unified Institutional Score Composite Signal | 39.7 / 100 (SELL) | 58.2 / 100 (HOLD) | Higher Composite | BHST |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BLTE vs BHST Buy Guide
BLTE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BHST
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BLTE nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.